title: Efficacy of interleukin-1 targeting treatments in patients with familial mediterranean Fever.
abstract: Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1-4) and 12 (4-50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p < 0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.
authors.affiliation: Department of Rheumatology, Dokuz Eylul University School of Medicine, 35340, Izmir, Turkey.
authors.forename: Pinar
authors.initials: P
authors.lastname: Cetin
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
authors.forename: Betul
authors.initials: B
authors.lastname: Sozeri
authors.forename: Ozlem
authors.initials: O
authors.lastname: Cam
authors.forename: Merih
authors.initials: M
authors.lastname: Birlik
authors.forename: Nurullah
authors.initials: N
authors.lastname: Akkoc
authors.forename: Fatos
authors.initials: F
authors.lastname: Onen
authors.forename: Servet
authors.initials: S
authors.lastname: Akar
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D016503:Drug Delivery Systems / Q000379:methods*; D010505:Familial Mediterranean Fever / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; C541220:canakinumab